

Anti-CD30 (Brentuximab), Chimeric Antibody

rev 10/20

CATALOG NO.: A2177-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant antibody to Brentuximab without the drug conjugation. The original antibody-drug conjugate (Brentuximab Vedotin) consists of an Anti-CD30 human-mouse chimeric IgG1 antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and results in apoptosis of tumorigenic cells. The original ADC received approval from the FDA to treat adult patients with relapsed or refractory Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.

ALTERNATE NAMES: cAC10-vcMMAE, SGN 35, SGN-35, Ki-1, D1S166E, TNFRSF8

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Human/Mouse chimeric / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human CD30

CAS NUMBER: 914088-09-8

MOLECULAR WEIGHT: 150.5 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CD20 (Rituximab), Chimeric Antibody (A1049)
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-VEGF (Bevacizumab), Humanized Antibody (A1045)
 Anti-IL-6 (Siltuximab), Chimeric Antibody (A2143)
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

FOR RESEARCH USE ONLY! Not to be used on humans.